Daily Archives: July 13, 2020

Aviation Week Network’s MRO Series Goes Virtual this Fall With MRO Asia-Pacific and MRO TransAtlantic

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) — Aviation Week Network today announced the move to virtual platforms for MRO Americas, MRO Asia-Pacific and MRO Europe, making the difficult decision not to hold these as in person events in 2020. Originally scheduled to take place in Dallas, Texas, September 1-3; Singapore, September 22-24; and Barcelona,

CNA Transitions to AIR Worldwide as its Primary Catastrophe Risk Management Platform

Boston, July 13, 2020 (GLOBE NEWSWIRE) — Catastrophe modeling firm AIR Worldwide announced that CNA has transitioned to AIR’s Touchstone solution as its primary catastrophe risk modeling platform. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “We are excited to leverage AIR’s powerful catastrophe modeling solution to support our multiple lines of business during the underwriting

Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe

Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia Ovid Therapeutics will receive an upfront payment of $20 million and additional payments of up to

Trip.com Group releases “2020 Dragon Boat Festival Holiday Big Data Report”

Diagram of Hot Airlines During Dragon Boat Festival Most popular flight routes throughout the Dragon Boat Festival (pictured). SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) — Leading international online travel services provider Trip.com Group has highlighted the latest positive trends in travel in its recently released “2020 Dragon Boat Festival Holiday Tourism Big Data Report” for

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today the completion of study subjects enrollment in Phase I trial of SARS-CoV-2 neutralizing monoclonal antibody injection (Product Code: JS016), developed jointly with Institute of Microbiology, Chinese